Heald Robert A, Modi Chetna, Cookson Jenny C, Hutchinson Ian, Laughton Charles A, Gowan Sharon M, Kelland Lloyd R, Stevens Malcolm F G
Cancer Research Laboratories, School of Pharmaceutical Sciences, University of Nottingham, Nottingham NG7 2RD, UK.
J Med Chem. 2002 Jan 31;45(3):590-7. doi: 10.1021/jm011015q.
Two short routes to novel methylated pentacyclic quinoacridinium salts have been devised. New compounds display telomerase-inhibitory potency (<1 microM) in the TRAP assay. 3,11-Difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (12d, RHPS4, NSC 714187) has a higher selectivity for triplex and quadruplex DNA structures than the 3,6,8,11,13-pentamethyl analogue (12c, RHPS3, NSC 714186) and a low overall growth-inhibitory activity in the NCI 60 cell panel (mean GI(50) 13.18 microM); in addition, the activity profile of 12d does not COMPARE with agents of the topoisomerase II class. Compound 12d is soluble in water, stable in the pH range of 5-9, efficiently transported into tumor cells, and is currently the lead structure for further elaboration in this new class of telomerase inhibitor.
已设计出两条合成新型甲基化五环喹吖啶鎓盐的简短路线。新化合物在端粒酶重复扩增法(TRAP)测定中显示出端粒酶抑制活性(<1 microM)。3,11 - 二氟 - 6,8,13 - 三甲基 - 8H - 喹[4,3,2 - kl]吖啶鎓甲磺酸盐(12d,RHPS4,NSC 714187)对三链和四链DNA结构的选择性高于3,6,8,11,13 - 五甲基类似物(12c,RHPS3,NSC 714186),并且在NCI 60细胞系中总体生长抑制活性较低(平均GI(50)为13.18 microM);此外,12d的活性特征与拓扑异构酶II类药物不同。化合物12d可溶于水,在pH值5 - 9范围内稳定,能有效转运至肿瘤细胞,目前是这类新型端粒酶抑制剂进一步优化的先导结构。